SEPRAFILM® and Your C-Sections

SEPRAFILM is a temporary, bioresorbable adhesion barrier proven to reduce the incidence, extent, and severity of adhesions in patients undergoing abdominal or pelvic laparotomy.1,2 Proven safe and effective in the presence of blood, SEPRAFILM reduces postoperative adhesions and related complications.1

Reduce adhesions with SEPRAFILM3-6

Adhesions can form after 46% to 65% of primary C-sections.3-6 In a cohort study of patients receiving SEPRAFILM at primary C-section, SEPRAFILM significantly reduced adhesions, resulting in faster procedure and delivery times at repeat C-section.4

Incidents of adhesions following C-sections

SEPRAFILM application sites in C-sections7:

  • Hysterotomy
  • Fundus of uterus (under pelvic incision)

Indication
Seprafilm® Adhesion Barrier is indicated for the reduction of post-surgical adhesions in patients undergoing abdominal or pelvic laparotomy.

Important Safety Information
Seprafilm should not be wrapped around an intestinal anastomosis as such usage may result in increased anastomotic leak related events, such as abscess or peritonitis. The safety and effectiveness of Seprafilm has not been established in combination with other adhesion prevention products and/or in surgical procedures not within the abdominopelvic cavity. The safety and effectiveness of Seprafilm has also not been evaluated in cases of pregnancy, malignancy, or frank infection. The type and frequency of adverse events reported are consistent with events typically seen following abdominopelvic surgery when used as directed.

Please see full prescribing information.

Adhesions in C-sections

Learn more about the incidence and severity of adhesions in C-sections.

Adhesive disease

SEPRAFILM efficacy

Learn more about the efficacy of SEPRAFILM Adhesion Barrier.

Review

References:  1. Becker JM, Dayton MT, Fazio VW, et al. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg. 1996;183:297-306.  2. Diamond MP. Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): a blinded, prospective, randomized, multicenter clinical study. Fertil Sterility. 1996;66:904-910.  3. Morales KJ, Gordon MC, Bates GW Jr. Postcesarean delivery adhesions associated with delayed delivery of infant. Am J Obstet Gynecol. 2007;196(online):461.e1-461.e6.  4. Fushiki H, Ikoma T, Kobayashi H, Yoshimoto H. Efficacy of Seprafilm as an adhesion prevention barrier in cesarean sections. Obstet Gynecol Treatment. 2005;91:557-561.  5. Hamel K. Incidence of adhesions at repeat cesarean delivery. Am J Obstet Gynecol. 2007;196(online):e31-e32.  6. Lyell DJ, Caughey AB, Hu E, Daniels K. Peritoneal closure at primary cesarean delivery and adhesions. Obstet Gynecol. 2005;106:275-280.  7. SEPRAFILM Adhesion Barrier Prescribing Information. Cambridge, MA: Genzyme Biosurgery; 2008.